XNAS
HELP
Market cap534mUSD
Oct 08, Last price
10.72USD
1D
2.00%
1Q
56.04%
IPO
44.08%
Name
Cybin Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
-9.78%
Rev. gr., 5y
%
Revenues
-45m
L
Net income
-147m
L+29.98%
CFO
-132m
L+30.72%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.
Key people
Greg Cavers
Chief Financial Officer · since 2020
Aaron Bartlone
Chief Operating Officer · since 2023
Alex Nivorozhkin
Chief Scientific Officer · since 2020
Gabriel Fahel
Chief Legal Officer, Corporate Secretary · since 2022
Theresa Firestone
Lead Independent Director · since 2021
Paul Glavine
Director, Chief Growth Officer · since 2020
George Tziras
Director, Chief Business Officer · since 2023
Grant Froese
Independent Director · since 2020
Eric Hoskins
Independent Director · since 2020
Mark Lawson
Independent Director · since 2020
Headquarters & legal address
Suite 5600
100 King Street West
Toronto, ON M5X 1C9
CA
100 King Street West
Toronto, ON M5X 1C9
CA
Previous name
CLARMIN EXPLORATION INC.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑07 | 2018‑07 | 2017‑07 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||